leisure time -WSS

leisure time

author：fashion 2025-09-29 12:30:07 - browse：624

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

knowledge

entertainment

WSS

Private equity could exacerbate cardiology's overuse problem, experts fear

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA panel endorses Alnylam’s heart drug — after picking it apart

Trump demands the U.S. pay no more for drugs than other countries … again

Heart attack and stroke risk calculators need revising

Acelyrin, a rare IPO success, stumbles in its first big test

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Medical records are filled with copy

Continuity nursing helped my family in our darkest PICU moments

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Virginia high school admissions case could be legal follow

Heart attack and stroke risk calculators need revising

FDA panel endorses Alnylam’s heart drug — after picking it apart

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Trump demands the U.S. pay no more for drugs than other countries … again

Alkermes shareholders re

Jerome Adams on the need for new antivirals for Covid

explore

Food makers to regulators: Ultra

What does generative AI mean for health care? We asked experts

Generate Biomedicines machine learning biotech raises $273M

Will the IRA bring competition to the biologics market?

Hollywood unions extend contract negotiations for actors

Walmart eyes Medicare Advantage provider ChenMed

knowledge

entertainment

entertainment

focus